trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Uncooked cornstarch is used as a standard dietary treatment to prevent dangerously low blood sugar in people with glycogen storage disease type I.

the verdict
INSUFFICIENT LEANING
Recorded sources
6 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Uncooked cornstarch is used as a standard dietary treatment to prevent dangerously low blood sugar in people with glycogen storage disease type I?

Unclear. Multiple sources indicate uncooked cornstarch is used as a dietary treatment to prevent hypoglycemia in glycogen storage disease type I, with one review calling regular doses essential for preventing hypoglycemia. However, the evidence is largely from small studies and reviews that do not explicitly establish it as the standard treatment.

Verdict: PARTIAL LEAN · 6 sources for, 0 against · Last checked

The private library was unavailable for some searches in this check. Missing library results are not evidence against the claim.

Evidence for · 6
Glycogen Storage Disease Type I and III and Pyruvate Carboxylase Deficiency: Results of Long‐Term Treatment with Uncooked Cornstarch
1988
Get citation
ULLRICH, K., SCHMIDT, H., & TEEFFELEN‐HEITHOFF, A. v. (1988). Glycogen Storage Disease Type I and III and Pyruvate Carboxylase Deficiency: Results of Long‐Term Treatment with Uncooked Cornstarch. doi.org. https://doi.org/10.1111/j.1651-2227.1988.tb10695.x

See more details
More for · 5
Use of modified cornstarch therapy to extend fasting in glycogen storage disease types Ia and Ib -
Get citation
Use of modified cornstarch therapy to extend fasting in glycogen storage disease types Ia and Ib - PMC Lock. (n.d.). pmc.ncbi.nlm.nih.gov. https://pmc.ncbi.nlm.nih.gov/articles/PMC3808112/

Development of minimally invasive 13C-glucose breath test to examine different exogenous carbohydrate sources in patients with glycogen storage disease type Ia
2022
Get citation
Development of minimally invasive 13C-glucose breath test to examine different exogenous carbohydrate sources in patients with glycogen storage disease type Ia. (2022). doi.org. https://doi.org/10.1016/j.ymgmr.2022.100880

Effect of Continuous Glucose Therapy Begun in Infancy on the Long-Term Clinical Course of Patients with Type I Glycogen Storage Disease
1999
Get citation
Effect of Continuous Glucose Therapy Begun in Infancy on the Long-Term Clinical Course of Patients with Type I Glycogen Storage Disease. (1999). doi.org. https://doi.org/10.1097/00005176-199908000-00008

Glycogen Storage Disease Type Ia: Current Management Options, Burden and Unmet Needs.
2021
Get citation
TGJ, D., DF, R., A, A., F, d. B., ML, C., SC, G., P, L., N, L. M., C, F. M. d. S., R, R., A, R., H, S., RN, G., V, V., & J, M. (2021). Glycogen Storage Disease Type Ia: Current Management Options, Burden and Unmet Needs.. doi.org. https://doi.org/10.3390/nu13113828

A Novel Approach to Treatment of Hepatic Glycogen Storage Diseases: a Study Based on the Use of Uncooked Sweet Manioc Starch
2017
Get citation
A Novel Approach to Treatment of Hepatic Glycogen Storage Diseases: a Study Based on the Use of Uncooked Sweet Manioc Starch. (2017). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT03871673

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work